Union Pacific Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since January 2009 — Data Talk
Union Pacific Corporation (UNP) is currently at $227.04, down $1.97 or 0.86%
--Would be lowest close since Nov. 30, 2023, when it closed at $225.27
--Currently down 11 of the past 12 days
--Currently down nine consecutive days; down 7.91% over this period
--Longest losing streak since Jan. 20, 2009, when it fell for nine straight trading days
--Worst nine day stretch since the nine days ending March 17, 2023, when it fell 9.01%
--Down 4.27% month-to-date; on pace for worst month since Sept. 2023, when it fell 7.68%
--Down 7.56% year-to-date
--Down 17.94% from its all-time closing high of $276.69 on March 30, 2022
--Up 17.93% from 52 weeks ago (May 31, 2023), when it closed at $192.52
--Down 11.63% from its 52-week closing high of $256.91 on Feb. 23, 2024
--Up 17.93% from its 52-week closing low of $192.52 on May 31, 2023
--Traded as low as $226.01; lowest intraday level since Nov. 30, 2023, when it hit $220.65
--Down 1.31% at today's intraday low
All data as of 10:22:55 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 29, 2024 10:40 ET (14:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks